Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis

The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several these successful are based on adenoviral vector platform. mass manufacturing poses great challenges, especially in context a where extremely large quantities must be produced quickly at an affordable cost. In this work, two baseline processes for production vaccine, B1 and P1, were designed, simulated economically evaluated with aid software SuperPro Designer. used batch cell culture viral step, titer 5 × 1010 particles (VP)/mL both stainless-steel disposable equipment. P1 perfusion 1 1012 VP/mL exclusively Both sized to produce 400 M/yr vaccine doses. led smaller cost per dose than ($0.15 vs. $0.23) required much capital investment ($126 M $299 M). media facility-dependent expenses found main contributors operating results indicate can practically manufactured scale low